We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Mesa Biotech Showcases PCR Testing Platform at Clinical Expo

By LabMedica International staff writers
Posted on 02 Aug 2018
Print article
Image: The Accula Dock system (Photo courtesy of Mesa Biotech).
Image: The Accula Dock system (Photo courtesy of Mesa Biotech).
Mesa Biotech Inc. (San Diego, CA, USA), a privately-held, molecular diagnostic company, showcased its affordable PCR (polymerase chain reaction) testing platform designed specifically for point-of-care (POC) infectious disease diagnosis at the 70th Annual American Association of Clinical Chemistry Scientific Meeting & Clinical Lab Expo (AACC). AACC 2018 was held on July 29 – August 2, 2018, in Chicago, Illinois, USA.

Mesa Biotech designs, develops, manufactures and commercializes next generation molecular diagnostic tests, bringing the superior diagnostic performance of nucleic acid PCR amplification to the POC. At AACC 2018, Mesa Biotech showcased its novel Accula System – a palm-sized, reusable dock with disposable test cassettes that offers the simplicity, convenience and procedural familiarity of traditional POC rapid immunoassays, while providing the superior sensitivity, specificity and information content of laboratory-based PCR testing. Test results are available in approximately 30 minutes to guide same-day treatment decisions. The handheld platform delivers flexibility in POC, ranging from the physician's office and walk-in clinics to emergency rooms. Accula Flu A/Flu B, the first commercialized test on the platform, is indicated for use with nasal swab collection that is less invasive than nasopharyngeal swabs and allows for a more comfortable specimen collection experience for the patient.

"We are excited to be a part of this leading industry conference and showcase our recently launched testing platform to the more than 20,000 attendees," said Hong Cai, Co-founder and Chief Executive Officer, Mesa Biotech, Inc. "AACC is an important opportunity for us to connect with global leaders, highlight new assays under development and identify additional partnership opportunities."

Related Links:
Mesa Biotech

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Automatic Nucleic Acid Extractor
GeneRotex 24

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.